Artemether‑Lumefantrine Tablets are a fixed‑dose artemisinin‑based combination antimalarial.
Artemether: A fast‑acting artemisinin derivative that rapidly reduces parasite density and relieves symptoms.
Lumefantrine: A long‑acting blood schizonticide that eliminates remaining parasites and prevents treatment failure and recurrence.
The combination provides strong synergistic activity, high cure rates, and helps prevent the development of drug resistance.
Indications
For the treatment of acute uncomplicated malaria caused by Plasmodium falciparum (including multidrug‑resistant strains) and Plasmodium vivax in adults and children.
Key Features
Rapid parasite clearance and quick fever resolution
High efficacy and low recurrence rate
Well‑tolerated and widely used globally
Standard 3‑day oral treatment course
Available in pediatric and adult strengths
Manufactured under strict GMP standards
Complies with WHO, USP, EP pharmacopoeial requirements
Full dossiers available for international registration
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Prescription only medicine.
Contraindicated in patients with hypersensitivity to artemether, lumefantrine, or excipients.
May cause dizziness, headache, sleep disturbances, or gastrointestinal symptoms.
Use with caution in patients with cardiac disorders, hepatic or renal impairment.
Not suitable for severe malaria; parenteral antimalarials are required.
Administer under medical supervision.
